Amylin Pharmaceuticals Scrip Surges On Report Of New Sale Discussions
Tue, 04/24/2012 - 09:18 | 
Shares of diabetes drug manufacturer Amylin Pharmaceuticals Inc. soared on April 23 accompanying a report the firm is reaching out to prospective buyers on a possible sale.
Sun Pharmaceutical Industries Ltd. has announced that USFDA has given nod for its Abbreviated New Drug Application for generic edition of Zyprexa, Olanzapine tabs USP, 2.5mg, 5mg, 7.5mg,10mg, 15mg and 20mg
Pfizer Pfizer is determined on throwing away noncore biz groups. AstraZeneca is intent on appending any small firm, which might bring returns.
Tags: Amylin Pharma’s Diabetes Injection Bags USFDA Nod
After two earlier rejections in 2010, Amylin Pharmaceutical’s diabetes medication Bydureon lastly bagged the Food and Drug Administration’s (FDA) nod on January 27.
Spectrum Pharmaceuticals has inked a deal to get hold of licensing rights to sell ZEVALIN (ibritumomab tiuxetan) jab for intravenous usage outside of the United States from Bayer Healthcare.
Fitch Ratings said that the 2012 viewpoint for the Indian pharmaceutical sector is static. The agency projects credit profiles to stay stable given that long-standing profits and profitability outlooks stay intact with moderate capital expenditure.
